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The Cornelia de Lange syndrome (CdLS) is a multisystem developmental disorder characterized by facial dysmor-
phia, upper-extremity malformations, hirsutism, cardiac defects, growth and cognitive retardation, and gastroin-
testinal abnormalities. Both missense and protein-truncating mutations in NIPBL, the human homolog of the
Drosophila melanogaster Nipped-B gene, have recently been reported to cause CdLS. The function of NIPBL in
mammals is unknown. The Drosophila Nipped-B protein facilitates long-range enhancer-promoter interactions and
plays a role in Notch signaling and other developmental pathways, as well as being involved in mitotic sister-
chromatid cohesion. We report the spectrum and distribution of NIPBL mutations in a large well-characterized
cohort of individuals with CdLS. Mutations were found in 56 (47%) of 120 unrelated individuals with sporadic
or familial CdLS. Statistically signiﬁcant phenotypic differences between mutation-positive and mutation-negative
individuals were identiﬁed. Analysis also suggested a trend toward a milder phenotype in individuals with missense
mutations than in those with other types of mutations.
Introduction
Cornelia de Lange syndrome (CdLS [MIM 122470]),
which was recognized as a distinct entity 170 years
ago, is a clinically heterogeneous developmental disorder
characterized by facial dysmorphia, upper-extremity
malformations, hirsutism, cardiac defects, growth and
cognitive retardation, and gastrointestinal abnormalities
(Brachmann 1916; de Lange 1933). The distinctive facial
features include synophrys, long eyelashes, depressed na-
sal bridge with an uptilted nasal tip and anteverted nares,
thin upper lip with downturned corners of the mouth,
and posteriorly rotated low-set ears. Abnormalities in
the upper extremities range from subtle changes in the
phalanges and metacarpal bones and small hands to oli-
godactyly and severe reduction defects. Gastrointestinal
abnormalities include gastroesophageal reﬂux, intestinal
malrotation, and pyloric stenosis. Additional relatively
frequent features include hearing loss, ophthalmologic
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ﬁndings (ptosis and myopia), palatal abnormalities, gen-
itourinary abnormalities (cryptorchidism and hypospa-
dias), cardiac septal defects, and congenital diaphrag-
matic hernias. Growth retardation is an almost universal
ﬁnding in CdLS and typically has a prenatal onset. Stan-
dard growth curves have been established for height,
weight, and head circumference (Kline et al. 1993a). The
mental retardation in CdLS is often severe, with a mean
IQ of 53 (range 30–86) (Kline et al. 1993b). Many pa-
tients also demonstrate autistic-like behavior and self-
injurious behavior (Jackson et al. 1993).
The clinical features seen in individuals with classic
CdLS are striking and easily recognizable; however,
there is marked variability, and a milder phenotype has
been consistently described (Ireland et al. 1993; Saul et
al. 1993; Selicorni et al. 1993; Van Allen et al. 1993).
Indeed, even the ﬁrst reported descriptions of CdLSwere
markedly discrepant in phenotype; Brachmann (1916)
described major upper-limb–reduction abnormalities,
whereas de Lange (1933) reported no limb-reduction
defects. This phenotypic variability and the lack of a
diagnostic marker have complicated the diagnosis and
genetic counseling for CdLS.
The prevalence of CdLS is estimated to be as high as
1/10,000 (Opitz 1985), and most cases appear to be
sporadic. Pedigree analyses of several families demon-
strate autosomal dominant inheritance with both ma-
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ternal and paternal transmission (Robinson et al. 1985;
Bankier et al. 1986; Halal and Silver 1992; Feingold
and Lin 1993; Chodirker and Chudley 1994; Kozma
1996; Russell et al. 2001;McConnell et al. 2003). Given
autosomal dominant inheritance, cases of apparently
unaffected parents who have multiple children with
CdLS were hypothesized to be the result of germline
mosaicism (Beratis et al. 1971; Lieber et al. 1973; Fryns
et al. 1987; Naguib et al. 1987; Krajewska-Walasek et
al. 1995). This hypothesis of germline mosaicism was
further supported by the identiﬁcation of several fam-
ilies in which an unaffected parent had multiple affected
children through different partners (Krantz et al. 2001).
Two recent reports document that mutations in
NIPBL cause CdLS (Krantz et al. 2004; Tonkin et al.
2004). The types of mutations identiﬁed in NIPBL in-
cluded missense, splice site, nonsense, and frameshift.
Severe protein-truncating mutations likely lead to hap-
loinsufﬁciency of the NIPBL protein. Haploinsufﬁciency
of NIPBL was documented as a disease mechanism in
the report of a child with classic features of CdLS who
was stillborn but was found prenatally to have a large,
cytogenetically visible deletion of chromosome 5p13.1-
14.2 (Hulinsky et al. 2003). This deletion would be
predicted to encompass the NIPBL gene. To our knowl-
edge, there have not been any other reported cases of
constitutional deletions of this region. The hypothesis
of germline mosaicism was also validated by the iden-
tiﬁcation of the same NIPBL mutation in affected sib-
lings born to unaffected mutation-negative parents
(Krantz et al. 2004).
The prevalence of NIPBL mutations in a large pop-
ulation of individuals with CdLS and the correlation of
speciﬁc mutations with phenotypic characteristics have
not previously been formally addressed. This article re-
ports the systematic molecular and cytogenetic evalu-
ation of 120 individuals with CdLS for disruptions in
the NIPBL gene. We have identiﬁed mutations in 47%
of tested probands and have examined this cohort for
genotype-phenotype correlations.
Subjects and Methods
Clinical Evaluation
All patients and family members were enrolled in the
study under an institutional review board–approved
protocol of informed consent at The Children’s Hospital
of Philadelphia. All subjects were evaluated by one or
more clinical dysmorphologists (I.D.K, A.D.K, and
L.G.J) with experience with CdLS. Clinical histories and
photographs were obtained routinely for all probands,
as well as for any other affected familymembers.Clinical
records were reviewed for the presence of other CdLS-
associated anomalies, such as deafness; cleft palate; and
cardiac, ophthalmologic, gastrointestinal, genitourinary,
and renal anomalies. For the purposes of the genotype-
phenotype studies, only probands (no other family mem-
bers) were included. This may result in a bias toward
the more severe phenotype; however, as familial recur-
rences are extremely rare, it was not possible to perform
a separate analysis on the small number of affected fam-
ily members. Although all probands had characteristic
facial features that were part of the criteria for their
inclusion into the study, we chose to further stratify the
CdLS cohort on the basis of the severity of three phe-
notypic parameters: limb differences, growth, and cog-
nitive function (summarized in table 1).
Limb malformations were classiﬁed by the presence
or absence of reduction defects in the upper extremities,
as follows: class I (mild), no reduction defect; class II
(moderate), partial reduction defect/oligodactyly (12
digits on each hand); and class III (severe), severe re-
duction defect/oligodactyly (2 digits on either hand).
A score for severity of the physical growth parameters
was calculated by averaging the percentiles for weight,
height, and head circumference that were plotted on sex-
and age-standardized growth curves for individuals with
CdLS (Kline et al. 1993a). Growth parameters were clas-
siﬁed as follows: class I (mild), average growth param-
eters and 175th percentile on CdLS growth curves; class
II (moderate), average growth parameters and 25th–
75th percentile on CdLS growth curves; and class III
(severe), average growth parameters and !25th percen-
tile on CdLS growth curves. Cognitive function was the
most difﬁcult parameter to standardize, because most
individuals with CdLS who enrolled in the study had
not received formal developmental evaluations and be-
cause of the inherent difﬁculty in comparing the devel-
opmental abilities of individuals of various ages. We
determined classiﬁcations of developmental/cognitive
abilities on the basis of deviation from age-appropriate
standards as follows: class I (mild), motor milestones !2
years delayed from normal standards, with development
of speech and communication skills in older individuals;
class II (moderate), delay in reaching motor milestones
12 years behind normal developmental standards, with
limited speech and communication; class III (severe),
profound delay in achieving motor milestones, with a
lack of meaningful communication. Clinical stratiﬁca-
tion of all probands was performed without knowledge
of mutational status.
Mutational Analysis
Genomic DNA was isolated from peripheral blood
lymphocytes (Gentra Systems). Parental DNAwas avail-
able for 41 (85%) of 48 patients with sporadic CdLS
who had NIPBL mutations. DNA from both parents
was available in 25 (52%) of 48 patients, and DNA from
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only one parent was available in 16 (33%) of 48 pa-
tients. The entire NIPBL coding region (exons 2–47)
was screened for mutations. Primer sequences, annealing
temperatures, and sizes of PCR products are listed in
table A1 (online only). Primer pairs were designed to
amplify exons, exon/intron boundaries, and short ﬂank-
ing intronic sequences. Larger exons were subdivided to
allow for optimal product lengths. All PCR reactions
were performed in a 25-ml reaction volume containing
75 ng of genomic DNA, 1 U of AmpliTaq Gold (Applied
Biosystems), 20 pmol of each primer, 75 mM of each
dNTP, 10# PCR buffer II (Applied Biosystems), and 1.0
mM or 1.5 mM of MgCl2 (Applied Biosystems). Cycling
parameters were as follows: 36 cycles at 94C for 30 s,
at 51C–60C for 45 s, and at 72C for 30 s, with a last
extension step at 72C for 5 min. Ampliﬁcations for
exons 6, 11, 21, 26, 30, 44, and 45 were performed with
10 cycles at 95C for 30 s, at 51C–62C for 30 s, and
at 72C for 35 s, followed by 25 cycles at 95C for 30
s, at 51C–62C for 30 s, and at 72C for 45 s, increasing
by 5 s for each cycle (table A1 [online only]). Mutational
analysis of the amplimers was performed using confor-
mation-sensitive gel electrophoresis (CSGE) with stan-
dard protocols (Ganguly et al. 1993). PCR products cor-
responding to all altered migration patterns (shifts) on
CSGE were puriﬁed using QIAquick PCR puriﬁcation
kit (Qiagen) and were sequenced bidirectionally on an
ABI 377 sequencer.
Genotype-Phenotype Correlations
Genotype-phenotype correlations were assessed using
contingency-table analysis. This was performed for the
three categories (mild, moderate, and severe) of each
phenotypic parameter (limb defect, growth, and devel-
opment), with a focus on the presence versus the absence
of a mutation in NIPBL and on individuals with mis-
sense mutations versus those with other types of mu-
tations. For analysis of the mutation-positive versus mu-
tation-negative individuals, the x2 test with 2 df was
used. For the analysis of missense versus other types of
mutations, Fisher’s exact test was used. The signiﬁcance
threshold was set at .P  .05
FISH Analysis
FISH studies were performed on metaphase chro-
mosomes prepared from peripheral blood lymphocytes
by use of standard techniques (Krantz et al. 1997). FISH
was performed with the NIPBL-containing BAC RP11-
14I21 (NCBI accession number AC018853.3) on 28mu-
tation-negative individuals (4 familial and 24 sporadic
CdLS cases) to evaluate for the possibility of a large but
submicroscopic deletion encompassing the NIPBL gene.
BAC DNA was isolated (Perfect Prep Plasmid XL [Ep-
pendorf]) and labeled by nick translation in the presence
of Spectrum Red dUTP (Vysis). The labeled BAC probe
was dissolved in LSI/WCP hybridization buffer (Vysis),
and 10 mg of Human Cot-1 DNA (Invitrogen) was added
per 1 mg of labeled BAC RP11-14I21 probe. TelVysion
probe 5p and/or 5q (Vysis) (in accordance with the man-
ufacturer’s instructions) and 100 ng of labeled BAC
probe per micoscope slide were codenatured under a
coverslip for 2 min on a 75C slide warmer and were
hybridized at 37C for ∼16 h in a humid chamber. Slides
were subjected to two posthybridization washes—wash
1 (0.4 # saline-sodium citrate [SSC]; 0.3% NP-40) at
73C for 2 min and wash 2 (2 # SSC; 0.1% NP-40) at
room temperature for 1 min—and were counterstained
with DAPI II (Vysis). A Nikon microscope, equipped
with the appropriate ﬁlters, was used to visualize each
slide. CytoVision software version 3.1, build 10 (Applied
Imaging), and a CCD camera were used to capture FISH
images.
Results
Study Population
The study population consisted of 120 subjects with
CdLS, including 106 sporadic and 14 familial cases.
Linkage to the NIPBL locus at 5p13.1 was reported
elsewhere in 11 of the 14 families, with the identiﬁcation
of mutations in NIPBL in 2 of these families (Krantz et
al. 2004). In one family, a missense mutation in the ﬁrst
codon (M1K) was identiﬁed in three affected half-sib-
lings who each had a different father. The mutation was
not present in DNA extracted from lymphocytes in their
mother or in the two fathers from whom samples were
available. In the second family, a splice site mutation
(67635GrT) in the intron between exons 39 and 40
was identiﬁed in two affected siblings but not in DNA
isolated from lymphocytes in either parent. The study
population also included four previously reported, un-
related patients with CdLS with unique de novo muta-
tions in NIPBL (Krantz et al. 2004).
Spectrum of NIPBL Mutations Detected
The 120 subjects with CdLS were screened forNIPBL
coding-region mutations. Exons 2–47 and ﬂanking in-
tron sequences were ampliﬁed by PCR and were ana-
lyzed by use of CSGE. All products with variant migra-
tion proﬁles (band shifts) on CSGE were sequenced
bidirectionally. NIPBL mutations were identiﬁed in 56
patients (47%) with CdLS (7 familial and 49 sporadic)
(table 2 and ﬁg. 1). A total of 51 different mutations
were identiﬁed and comprised 21 frameshift, 12 mis-
sense, 10 nonsense, and 8 splice-site mutations. All iden-
tiﬁed mutations were private, except for four (8%): a 2-
bp deletion of exon 10 (2479delAG), in two unrelated
patients; a nonsense mutation (R1536X) of exon 22, in
Table 2
Summary of Mutations in NIPBL Identiﬁed in Probands with CdLS
Exon and Mutation Type Effect on Protein Fathera Mothera Number
2:
2 TrA; M1K Missense No initiating methionine Negative Negative Familial
61ArG Splice site … NA Negative 1
3:
150delG Frameshift Truncates protein 27 aa downstream Negative Negative 1
655ArG Splice site … Negative Negative 1
199del10; 199ins13b Complex Truncates protein 9 aa into insertion NA NA 1
7:
6112ArG Splice site … NA Negative 1
742delCT Frameshift Truncates protein 8 aa downstream NA NA 1
9:
961delA Frameshift Truncates protein 7 aa downstream NA NA 1
R479X Nonsense Truncates protein Negative Negative 1
10:
1546insG Frameshift Truncates protein 5 aa downstream Negative Negative 1
1669insC Frameshift Truncates protein 11 aa downstream NA Negative 1
1902insA Frameshift Truncates protein 2 aa downstream Negative Negative 1
2479delAG Frameshift Truncates protein 2 aa downstream Negative Negative 2
2520delT Frameshift Truncates protein 6 aa downstream Negative Negative 1
2969delG Frameshift Truncates protein 1 aa downstream NA NA 1
3023delTGTCT Frameshift Truncates protein 2 aa downstream NA Negative 1
3057delTAGA Frameshift Truncates protein 23 aa downstream Negative Negative 1
3060delAGAG Frameshift Truncates protein 22 aa downstream Negative Negative 1
R797X Nonsense Truncates protein NA Negative 1
R832X Nonsense Truncates protein Negative NA 1
E977X Nonsense Truncates protein Negative Negative 1
S1024X Nonsense Truncates protein NA Negative 1
15:
3736CrG; A1246G Missense … Negative Negative 1
17:
3969insG Frameshift Truncates protein 6 aa downstream Negative Negative 1
3935TrC; L1312P Missense … NA Negative 1
18:
S1398X Nonsense Truncates protein NA Negative 1
20:
S1459X Nonsense Truncates protein Negative Negative 1
21:
4556delAAAAA Frameshift Truncates protein 1 aa downstream Negative Negative 1
22:
R1536X Nonsense Truncates protein Negative (1), NA (2) Negative (2), NA (1) 3
4567delC Frameshift Truncates protein 1 aa downstream NA NA 1
26:
R1723X Nonsense Truncates protein Negative Negative Familial
27:
R1758X Nonsense Truncates protein Negative Negative 1
28:
5366GrT; R1789L Missense … NA NA 1
5408ArT; D1803V Missense … NA Negative 1
29:
5567GrC; R1856T Missense … Negative Negative Familial
55741GrT Splice site … Negative Negative 1
35:
61093TrC Splice site … NA (2) Negative (1) 2
39:
67635GrT Splice site … Negative Negative Familial
40:
6892CrT; R2298C Missense … NA Negative 1
(continued)
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Table 2 (continued)
Exon and Mutation Type Effect on Protein Fathera Mothera Number
42:
6893GrA; R2298H Missense … Negative Negative 2
6934GrC; G2312R Missense … Negative Negative 1
7151delAAGAC Frameshift Truncates protein 3 aa downstream NA Negative Familial
43:
7210delC Frameshift Truncates protein 21 aa downstream NA Negative 1
7142GrC; G2381A Missense … NA Negative 1
7168GrA; A2390T Missense … Negative Negative 1
7318TrC; Y2440H Missense … Negative Negative 1
44:
73214ArG Splice site … Negative Positive Familial
7431delG Frameshift Truncates protein 30 aa downstream NA Negative 1
45:
7780delC Frameshift Truncates protein 16 aa downstream Negative Negative Familial
7825insG Frameshift Truncates protein 22 aa downstream Negative Negative 1
46:
78611GrC Splice site … Negative Negative 1
a NA p sample not available.
b Insertion of atcaacaggtgac.
three unrelated patients; a splice-site mutation in the
intron upstream of exon 35 (61093TrC), in two un-
related patients; and a missense mutation (R2298H) of
exon 40, in two unrelated patients.
In 49 (46%) of the 106 individuals with sporadic
CdLS, 44 different mutations were identiﬁed. Of these,
14 (32%) were small deletions, and 6 (14%) were in-
sertions—5 were single–base-pair insertions, and 1 was
a complex deletion/insertion mutation with a net inser-
tion of 3 bp. All deletions and insertions led to frame-
shifts that resulted in a prematurely truncated protein
product. The deletion 2479delAG in exon 10 was seen
in two unrelated patients with sporadic CdLS. Nine
(20%) of the different mutations had single–base-pair
changes that led to immediate stop codons. Four (44%)
of the nonsense mutations were found in exon 10. The
nonsense mutation R1536X in exon 22 was identi-
ﬁed in three unrelated patients with sporadic CdLS.
In one patient with sporadic CdLS with a de novo
t(14q;21q)(q32;q11) (Wilson et al. 1983), the nonsense
mutation S1459X in exon 20 of NIPBL was identiﬁed
and was not present in either patient’s parents, sug-
gesting that the balanced de novo translocationmay rep-
resent an unrelated event.
Seven patients (16%) with sporadic CdLS had differ-
ent mutations predicted to lead to alterations in splicing.
The six splice-site mutations were not identiﬁed in avail-
able parental samples (six mothers and three fathers) or
in the 150 control patient samples.
Of the 44 mutations identiﬁed in patients with spo-
radic CdLS, 10 (23%) resulted in the substitution of a
single amino acid. These substitutions were predicted to
result in missense mutations by three criteria: absence
in parental samples, absence in control samples, and
evolutionary conservation of the altered amino acid.
One missense mutation—R2298H in exon 40—was
identiﬁed in two unrelated patients. The missense mu-
tations identiﬁed included A1246G (exon 15), L1312P
(exon 17), R1789L (exon 28), D1803V (exon 28),
R2298C (exon 40), R2298H (exon 40), G2312R (ex-
on 40), G2381A (exon 42), A2390T (exon 42), and
Y2440H (exon 43). These amino acids were, in general,
highly conserved throughout evolution (ﬁg. 2). These
mutations were not identiﬁed in available parental sam-
ples or in the 150 control patient samples.
In one apparent familial case of CdLS (reported else-
where as family XII [Krantz et al. 2001])—which was
excluded from subsequent linkage analyses, since it
showed an atypical inheritance pattern with two affected
male ﬁrst cousins born to unaffected sisters—the two
affected males were found to carry different de novo
mutations in NIPBL. In one child, an A1246G missense
change in exon 15 was identiﬁed, whereas, in his affected
cousin, a 78611GrC splice-site change was identiﬁed
in the intron upstream of exon 46. Neither mutation
was identiﬁed in either of the two sets of parents or in
the other cousin. The maternal 5p13 regions ﬂanking
NIPBL (including intragenic SNP markers) in the af-
fected individuals were not shared (data not shown).
Paternity was conﬁrmed in both cases.
Mutations were identiﬁed in 7 (50%) of 14 familial
cases of CdLS. Mutations in NIPBL were previously
reported in two of these families. In the ﬁrst family, a
missense mutation in the ﬁrst codon (M1K) was iden-
tiﬁed in three affected siblings, all of whom had different
fathers, and was not present in the mother or in the two
Figure 1 Facial features and limb ﬁndings in mutation-positive individuals with CdLS. Note the variability of features even among
individuals with similar mutation types.
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Figure 2 Evolutionary conservation of amino acid residues altered by missense mutations in NIPBL. A comparison of amino acids and
the ﬂanking sequence altered by 11 of the unique missense mutations in human (NIPBL), rat, mouse, and Drosophila is depicted. The mutated
amino acid residue is shaded gray. Amino acid residue 2298 was mutated in three individuals—two had an R2298H change, and one had an
R2298C change. The missense mutation M1K in the initiation codon is not depicted, since it is conserved in all species.
fathers available for testing (in all familial cases, mu-
tational analysis of parental samples was performed on
DNA extracted from lymphocytes, and mosaicism in
other tissues cannot be excluded). In the second family,
a splice-site mutation (67635GrT) segregatedwith the
CdLS phenotype in two affected siblings and was not
identiﬁed in either parent (Krantz et al. 2004). Four of
the ﬁve remaining mutation-positive families had been
linked to the NIPBL locus in a previous study (Krantz
et al. 2004). In the ﬁrst family, a nonsense mutation,
618 Am. J. Hum. Genet. 75:610–623, 2004
Table 3
Polymorphisms in NIPBL Identiﬁed in
Affected Individuals, Family Members,
and/or Controls
Polymorphism Located in Exon
23061CrAa,b 3
611102ArGc 6
2021ArG; N674Sa,b 10
2451CrT; D817Dc 10
357514ArGa 14
3616ArG; I1206V 14
385552ArGa,b 16
408853TrCc 17
358659GrA 17
423953TrCc 18
4239152CrGc 18
424048CrTc 19
432196CrT 20
432135TrCc 20
456077ArGa 21
4560108delTa 21
45619TrAc 22
4561106CrTc 22
463424GrAc 22
4773GrT; L1591Lc 23
4777108delAa 24
492158GrAa,b 25
5575193TrCa 30
557592GrC 30
557518GrCc 30
571059ArGc 31
571078GrAc 31
586274delTTa,b 32
586312delATa 33
586330delATa,b 33
586352delTc 33
5874CrT; S1958Sa,b 33
5971ArG; N1994Sc 34
610954insA 35
61093TrCc 35
649894TrCc 38
649980ArGc 39
676435CrGa 40
695462ArGc 40
69559delTa 41
786139GrA 45
86988701delACAA 47d
a Found in patients, family members,
and/or normal controls.
b Previously reported by Krantz et al.
(2004).
c Found in patients and familymembers.
d In the 3′ UTR.
R1723X in exon 26, was identiﬁed in two affected
brothers; neither the parents nor the unaffected brother
have the mutation. In the second family, the two affected
siblings share a unique 5-bp deletion, 7151delAAGAC
in exon 42, resulting in protein truncation 3 aa down-
stream. The mother did not carry the change, and there
was no sample available from the father. An affected
brother and sister in the third family share a single–base-
pair deletion, 7780delC of exon 45; this deletion results
in premature protein truncation 16 aa downstream.Nei-
ther parent carried this mutation. In the fourth family,
with four affected siblings and a mildly affected mother,
a splice-site mutation, 73214ArG in exon 43, was
identiﬁed in the two affected siblings from whom sam-
ples were available, as well as in the affected mother. In
the ﬁnal family—which was not included in the initial
linkage studies, since the affected female sibling of the
proband was deceased and no sample was available—a
missense mutation, R1856T in exon 29, was identiﬁed
in the affected male child but was not present in either
parent or in an unaffected sibling. Paternity was con-
ﬁrmed in all familial cases (as part of the genomewide
and high-resolution linkage analysis using multiple poly-
morphic markers) for which a paternal sample was
available.
None of the 51 different mutations were observed in
150 ethnically matched control subjects. Forty-two se-
quence variants that are likely to represent neutral poly-
morphisms were observed in subjects with CdLS, un-
affected family members, and/or control individuals
(table 3). Three of the polymorphisms (N674S, N1994S,
and I1206V) in the coding region of NIPBL led to an
altered amino acid residue, whereas three (D817D,
L1591L, and S1958S) were silent. Thirty-six polymor-
phisms were identiﬁed in intronic sequences ﬂanking the
exons.
FISH Analysis
To evaluate the possibility of a submicroscopic dele-
tion encompassing the NIPBL gene, 28 probands with
CdLS (4 familial and 24 sporadic) in whom a NIPBL
mutation was not identiﬁed were analyzed by FISH with
an NIPBL-containing BAC probe (RP11-14I21). RP11-
14I21 encompasses ∼16 kb of sequence 5′ of the NIPBL
gene, nearly through exon 10 of NIPBL. No deletion
of RP11-14I21 was detected in any of the probands
analyzed.
Genotype-Phenotype Correlation
Because of the clinical heterogeneity observed in CdLS
(ﬁg. 1), we evaluated possible associations between the
NIPBL genotype and the severity of the phenotype (se-
verity of limb, growth, and developmental involvement).
The distribution of several major clinical features in our
study cohort is shown in table 4. The results of genotype-
phenotype correlation analysis, performed for each phe-
notypic parameter, with a focus on the presence versus
the absence of a mutation in NIPBL and on missense
mutations versus other types of mutations, are also sum-
marized in table 4. Statistically signiﬁcant ( ) dif-P ! .05
ferences were observed in the distribution of severity of
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Table 4
Distribution of Clinical Severity and Results of Genotype-Phenotype Correlation Analysis
PHENOTYPE AND
CLASSIFICATIONa
NO. OF MUTATION-POSITIVE
(%)
NO. OF
MUTATION-NEGATIVE
(%)
P
Missense
Frameshift, Splice Site,
and Nonsense
Mutation-Positive vs.
Mutation-Negative
(x2 Test)
Missense vs.
All Other Mutations
(Fisher’s Exact Test)
Limb reduction:
I 12 (92) 25 (60) 47 (75)
II 1 (8) 3 (7) 9 (14)
III 0 14 (33) 7 (11)
NA 0 1 1
.085 .029
Developmental delay:
I 3 (23) 1 (3) 12 (20)
II 6 (46) 10 (25) 27 (44)
III 4 (31) 29 (73) 22 (36)
NA 0 3 3
.014 .008
Growth retardation:
I 3 (33) 2 (7) 17 (47)
II 4 (44) 11 (38) 13 (36)
III 2 (22) 16 (55) 6 (17)
NA 4 14 28
.002 .057
NOTE.— for mutation-positive, and for mutation-negative individuals.np 56 np 64
a NA p Not assessed.
growth retardation and developmental delay among the
mutation-positive and mutation-negative groups, with
the mutation-positive group displaying a more severe
phenotype for these parameters. A similar trend was also
observed in the severity of limb defects, although, in this
case, the difference was not statistically signiﬁcant. In
comparing individuals with missense mutations versus
those with all other mutation types, it appeared that the
latter showed more severe phenotypes in all categories
(except possibly in growth retardation), although the
number of missense mutations was small.
Discussion
Through the combined use of genomewide linkage-ex-
clusion analysis and the mapping of a chromosomal re-
arrangement on chromosome 5p13, NIPBL was iden-
tiﬁed as a CdLS disease gene (Krantz et al. 2004; Tonkin
et al. 2004). In the present study, we have identiﬁed
mutations in 47% of a well-characterized cohort of 120
unrelated probands with sporadic and familial CdLS.
Mutation-detection rates among the sporadic and fa-
milial cases were comparable: 49 (46%) of 106 sporadic
cases and 7 (50%) of 14 familial cases had identiﬁable
mutations. We expected to detect NIPBL mutations in
all of the familial cases shown elsewhere to be positively
linked to the 5p13 region (Krantz et al. 2004); however,
in our present analysis, we have identiﬁed mutations in
only 6 of the 11 families available for mutational anal-
ysis. This indicates either that the methods used for
screening are not identifying all mutations in individuals
with CdLS or that additional genes in 5p13 may poten-
tially be responsible for the phenotype. Alternatively, the
linkage to 5p could be coincidental in the mutation-
negative families, and genes from elsewhere in the ge-
nome may be causative when mutated.
If NIPBL is the only CdLS disease gene, then our
mutation detection rate of only 47% may be partly the
result of the large size of the NIPBL gene and the use
of CSGE for mutational analysis. Factors that may ac-
count for missed mutations in the gene include (1) var-
iations in sequence beyond the immediate intron/exon
boundaries (such as regulatory regions or intronic se-
quence), (2) large intragenic deletions, (3) subtle se-
quence variations (such as point mutations), and (4)
difﬁculty in amplifying and sequencing several NIPBL
exons (e.g., exon 33) as a result of numerous poly-
morphisms. The multiple splice variants of this gene
have made it difﬁcult to screen cDNA accurately for
mutations, at this time, although this testing is currently
being optimized and will allow for improved detection
of intronic variations that lead to splice mutations as
well as complete exonic deletions. Large-scale deletions
of NIPBL were assayed in those individuals in whom
an NIPBL mutation was not identiﬁed, and, in the 28
mutation-negative individuals studied by FISH, no de-
letion of the region was seen.
Alternatively, it is possible that the linkage established
in some of these small families was coincidental and
that a second CdLS gene may yet be identiﬁed elsewhere
in the genome to account for the phenotype in those
individuals in whom NIPBL mutations were not iden-
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tiﬁed. In our initial genomewide linkage exclusion anal-
ysis, three other regions were not excluded—chromo-
some 2q37, chromosome 10p13, and chromosome
14q24. These additional loci may contain a second
CdLS gene (Krantz et al. 2004). Likewise, several in-
dividuals with CdLS have been found to carry an ap-
parently balanced de novo translocation, suggesting
possible additional loci for a CdLS disease gene. The
child with the t(5;13)(p13.1;q12.1) was critical in the
identiﬁcation of NIPBL on chromosome 5p13 as the
cause, when mutated, of CdLS (Hulinsky et al. 2003;
Krantz et al. 2004; Tonkin et al. 2004). Two other de
novo balanced translocations have been reported. A de
novo t(3;17)(q26.3;q23.1) (Ireland et al. 1991) has been
extensively evaluated in a child with sporadic CdLS,
and, to date, no CdLS disease genes have been identiﬁed
(Tonkin et al. 2001, 2004). In the present study, a child
with a de novo t(14q;21q)(q32;q11) described else-
where (Wilson et al. 1983) has been found to carry a
de novo S1459X mutation in exon 20 of NIPBL. This
may indicate that this translocation is an unrelated
event. Although not all breakpoints in these rare trans-
location cases have been completely evaluated, they do
not appear to lend additional support to a potential
second locus, at this time.
To date, no mutations have been identiﬁed in exons
4–6, 8, 11–14, 16, 19, 23–25, 30–34, 36, 37, 41, and
47. Several exons have been found to have multiple
mutations, including exons 2, 3, 7, 9, 10, 17, 22, 28,
29, 40, 42, 43, and 45. There is a preponderance of
mutations identiﬁed in exon 10; however, this 1,625-
bp exon is ∼8 times the size of the average exon (∼200
bp) in the NIPBL gene. Exon 42, 200 bp in length, was
found to contain four different mutations in this cohort.
The majority of the 56 mutations identiﬁed are frame-
shift mutations (22 [∼39%; 16 deletions, 5 insertions,
and 1 complex]), followed by missense mutations (13
[∼23%]), nonsense mutations (12 [∼21%]), and splice-
site mutations (9 [∼16%]). The frameshift, nonsense,
and splice-site mutations are likely to result in a pre-
maturely truncated protein causing haploinsufﬁciency
of NIPBL (a disease mechanism that has been docu-
mented in the study of a child with CdLS and a large
cytogenetically visible deletion of chromosome 5p13.1-
14.2 that encompasses the NIPBL gene [Hulinsky et al.
2003]).
The missense mutations are important, in that they
may indicate residues of the NIPBL protein that are
functionally important. Of the 12 unique missense mu-
tations identiﬁed, 8 are in amino acid residues that are
evolutionarily conserved back to Drosophila (including
the M1K change in the initiation codon), and 3 are
evolutionarily conserved back to the mouse. One mis-
sense mutation, Y2440H, is present in an amino acid
located in a stretch of the human NIPBL protein not
seen in rat, mouse, or Drosophila.
As mentioned above, four mutations were identi-
ﬁed in unrelated individuals: 2479delAG in exon 10,
R1536X in exon 22, 61093TrC in the intronic se-
quence upstream of exon 35, and R2298H in exon 40.
An additional missense mutation in amino acid residue
2298 (R2298C) was seen in another individual. Even
among individuals with the same mutation, the phe-
notype demonstrated some variability. The three indi-
viduals with the R1536X mutation are all severely af-
fected in terms of growth and development; however,
two have severe limb-reduction defects, whereas the
third did not have a reduction defect. The two children
with the 2479delAG mutation are also severely affected
in terms of growth and development; however, one has
signiﬁcant limb-reduction defects, whereas the other
does not have a reduction defect. The two children with
the 61093TrC mutation and the two children with
the R2298H missense mutation are all moderately af-
fected in terms of growth and development, and none
have limb-reduction defects. This variability in severity
of phenotypes associated with identical mutations in-
dicates that mutations in NIPBL are not the sole de-
terminants of phenotype and that other factors (genetic
and/or environmental) can modify the clinical picture.
In six of the seven familial cases in which an NIPBL
mutation has been identiﬁed, germline mosaicism is the
most likely mechanism. In ﬁve of these families, DNA
from lymphocytes of both parents was available for
testing, and neither parent carried the mutations iden-
tiﬁed in the affected siblings (paternity was conﬁrmed
in all cases). In one family, with a 7151delAGAC, the
father was not available for testing; however, he re-
portedly has no clinical features of CdLS, and the mu-
tation was not seen in the mother. Autosomal dominant
transmission was demonstrated in the seventh family;
a 73214ArG mutation in exon 43 was identiﬁed in
the mildly affected mother and in the two of her four
affected daughters from whom samples were available.
In the 25 sporadic cases in which both parents were
available for screening, all mutations were found to
have arisen de novo, and, in the 17 sporadic cases in
which only one parent was available for screening, none
of these parents was found to carry the change seen in
the child. This would indicate that the vast majority of
mutations in individuals with CdLS arise as new events,
and, in the rare cases of familial recurrence in which
neither parent is affected, germline mosaicism is the
likely explanation. In the family in which two male ﬁrst
cousins have CdLS and their mothers, who are sisters,
are unaffected, the two affected males were each found
to carry a different de novo mutation (neither mutation
was seen in either set of parents, and direct sequencing
Gillis et al.: Genotype-Phenotype Analysis in CdLS 621
of the two cousins conﬁrmed that they did not share
the same mutation).
A large number of polymorphisms also have been
identiﬁed in NIPBL (table 3). There were three poly-
morphisms (N674S, I1206V, and N1994S) that resulted
in an amino acid substitution. All three of these were
identiﬁed in probands who had mutations in other ex-
ons, and, in the case of N1994S, the mutation was pre-
sent in one of the unaffected parents as well (for the
other two variants, both parents were not available for
screening). One polymorphism, N674S, was seen in
25 unrelated probands, 11 of whom had identiﬁable
NIPBL mutations, and in several controls. This amino
acid residue is conserved back to the mouse but is not
conserved in Drosophila. If the polymorphism was on
the nonmutant allele and had a mild functional effect
on the protein, it is possible that it could be a modiﬁer
of the phenotype. In the cohort of 11 probands with a
mutation and this polymorphism, there did not appear
to be a marked effect on phenotype. It is of interest that
the one individual with a missense mutation (A2390T)
who also had this polymorphism was the only one of
the probands with missense mutations to have limb-
reduction defects. Further work is needed to evaluate
this and other polymorphisms as potential modiﬁers of
the phenotype, through determination of allelic locali-
zation of these changes in relation to the mutation, as
well as through functional studies to assess their effects.
Comparisons were made of genotype-phenotype cor-
relations in mutation-positive andmutation-negative in-
dividuals, as well as in individuals with different types
of mutations. Severity of limb defects and retardation
in growth and cognitive development were evaluated
(outlined in tables 1 and 4). Mutations in NIPBL were
found in mildly and severely affected individuals with
CdLS. Similarly, in the group of probands with CdLS
and without identiﬁable mutations, there are also se-
verely and mildly affected individuals. The analysis of
genotype-phenotype associations demonstrated a trend
toward a more severe phenotype in mutation-positive
versus mutation-negative individuals. This indicates
that a subset of individuals with “mild” CdLS may have
a different genetic etiology causing their phenotype or
may have mutations in NIPBL that have not yet been
detected by use of CSGE.
We hypothesized that the missense mutations iden-
tiﬁed in NIPBL may result in either a milder phenotype
as a result of a less severe structural effect on the protein,
or, conversely, a more severe phenotype if the mutations
occurred in critical domains of the protein, causing a
dominant-negative effect. For these reasons, a similar
analysis was performed to compare genotype-pheno-
type correlations seen in individuals with missense and
all other types of mutations. This analysis suggests that
individuals with missense mutations may have a milder
phenotype; however, the number of individuals with
missense mutations is too small to reach deﬁnite con-
clusions at this time.
The role of NIPBL in mammals has yet to be eluci-
dated, and what is known about its function has come
from Drosophila studies. The Drosophila homolog of
NIPBL, Nipped-B, was identiﬁed through a screen for
mutations that reduce activation by the wing margin
enhancer in the presence of a gypsy insertion (Rollins
et al. 1999); gypsy insertions in the cut gene in Dro-
sophila are known to block a remote wing margin en-
hancer located 85 kb upstream of the promoter. This
long-range effect on transcription as well as its homol-
ogy to chromosomal adherins (proteins that have a role
in chromosome compaction and sister-chromatid co-
hesion) suggest that the Nipped-B protein performs an
architectural role in enhancer-promoter communication
(Rollins et al. 1999). These interactions have been dem-
onstrated to be involved in the regulation of multiple
developmental pathways in Drosophila, including the
Notch signaling pathway (Rollins et al. 1999). Recently,
a role for the Drosophila Nipped-B protein in sister-
chromatid cohesion has also been demonstrated, and a
model of how Nipped-B interacts with the cohesin pro-
tein complex to affect gene expression was proposed
(Rollins et al. 2004). The ability of distal enhancers to
activate promoters and to initiate transcription relies on
the coordinated interaction of multiple proteins and
protein complexes. The large number of additional pro-
teins that interact in these complexes suggests multiple
possibilities for modiﬁers of NIPBL and potential ad-
ditional CdLS disease genes.
In this study, we have shown that mutations in
NIPBL are detected, at present, in 47% of individuals
with either familial or sporadic CdLS. The mutations
are spread throughout the gene, and frameshift, non-
sense, splice-site, and missense mutations have been
identiﬁed. The majority of mutations are protein trun-
cating, likely leading to haploinsufﬁciency of the protein
product. The 12 unique missense mutations identiﬁed
in this screen will be important in characterizing func-
tionally important domains of this novel protein. There
appears to be a genotype-phenotype correlation in mu-
tation-positive and mutation-negative individuals and
possibly in individuals with missense mutations as com-
pared to those with all other mutation types. To un-
derstand the striking variability of the CdLS phenotype,
further work is needed to delineate the functionally im-
portant regions of the NIPBL protein, to characterize
the various splice isoforms in different tissues and dur-
ing development, to deﬁne the role of interacting pro-
teins, and to determine the effect of polymorphisms on
the coding and noncoding sequences of mutant and non-
mutant alleles.
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